NCT04591184View on ClinicalTrials.gov

A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

April 7, 2021

Primary Completion Date

December 6, 2023

Study Completion Date

December 6, 2023

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

Covigenix VAX-001 placebo

Placebo vaccine

BIOLOGICAL

Covigenix VAX-001

Active Covigenix VAX-001

Trial Locations (4)

9301

FARMOVS (PTY) Ltd., Bloemfontein

Unknown

National Center for Research and Training on Malaria, Ouagadougou

Institute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar

B3K 6R8

Canadian Centre for Vaccinology, Dalhousie University, Halifax

Sponsors
All Listed Sponsors
collaborator

Aegis Life, Inc.

UNKNOWN

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Clinical Pharma Solutions Inc

UNKNOWN

collaborator

Centre national de recherche et de formation sur le paludisme (CNRFP)

UNKNOWN

lead

Entos Pharmaceuticals Inc.

INDUSTRY